Evidence map›Paper›PMID 39272813›Full record

ArticleCancers2024

Rare Germline Variants in DNA Repair Genes Detected in

Viivi Kurkilahti, Venkat Subramaniam Rathinakannan, Erja Nynäs, Neha Goel, Kristiina Aittomäki, Heli Nevanlinna, Vidal Fey, Minna Kankuri-Tammilehto, Johanna Schleutker

Abstract read
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Viivi KurkilahtiCancer Research Unit and FICAN West Cancer Centre, Institute of Biomedicine, University of Turku and Turku University Hospital, 20014 Turku, Finland.
Venkat Subramaniam RathinakannanCancer Research Unit and FICAN West Cancer Centre, Institute of Biomedicine, University of Turku and Turku University Hospital, 20014 Turku, Finland.ORCID 0000-0002-7691-3872
Erja NynäsDepartment of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, 00280 Helsinki, Finland.ORCID 0000-0003-0681-9941
Neha GoelCancer Research Unit and FICAN West Cancer Centre, Institute of Biomedicine, University of Turku and Turku University Hospital, 20014 Turku, Finland.
Kristiina AittomäkiDepartment of Clinical Genetics, University of Helsinki and Helsinki University Hospital, 00250 Helsinki, Finland.
Heli NevanlinnaDepartment of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, 00280 Helsinki, Finland.
Vidal FeyCancer Research Unit and FICAN West Cancer Centre, Institute of Biomedicine, University of Turku and Turku University Hospital, 20014 Turku, Finland.ORCID 0000-0003-1388-5904
Minna Kankuri-TammilehtoDepartment of Clinical Genetics, Turku University Hospital, 20520 Turku, Finland.ORCID 0000-0003-4276-2970
Johanna SchleutkerCancer Research Unit and FICAN West Cancer Centre, Institute of Biomedicine, University of Turku and Turku University Hospital, 20014 Turku, Finland.ORCID 0000-0002-1863-0305

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBreast cancer is the most common malignancy, with a mean age of onset of approximately 60 years. Only a minority of breast cancer patients present with an early onset at or before 40 years of age. An exceptionally young age at diagnosis hints at a possible genetic etiology. Currently, known pathogenic genetic variants only partially explain the disease burden of younger patients. Thus, new knowledge is warranted regarding additional risk variants. In this study, we analyzed DNA repair genes to identify additional variants to shed light on the etiology of early-onset breast cancer.

methodsGermline whole-exome sequencing was conducted in a cohort of 63 patients diagnosed with breast cancer at or before 40 years of age (median 33, mean 33.02, range 23-40 years) with no known pathogenic variants in

resultsFive novel, deleterious variants in the genes

conclusionsTaken together, whole-exome sequencing yielded 72 deleterious variants, including 8 novel variants that may play a pivotal role in the development of early-onset breast cancer. Although more studies are warranted, we demonstrate that young breast cancer patients tend to carry multiple deleterious variants in one or more DNA repair genes.

Indexed as

BRCA1/2 negativeBreast cancerDNA repair genesearly onsetrare variants

Identifiers

PMID39272813
PMCPMC11393874

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.